BENITIONSClinical Trial Intelligence

Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT

Фаза 2 Завершено NCT02036970

ЗаболеваниеPulmonary Arterial Hypertension, Pulmonary Hypertension, Interstitial Lung Disease, Idiopathic Interstitial Pneumonia
ФазаФаза 2
СпонсорBiogen
СтатусЗавершено
Участники166 участн.
ВмешательствоBardoxolone methyl
Дата начала31.05.2014
Дата завершения19.01.2018
Публикация результатов23.07.2021

Кратко

This study assesses the safety and efficacy of bardoxolone methyl relative to placebo in patients with pulmonary hypertension to determine the recommended dose range, evaluate the change from baseline in 6-minute walk distance (6MWD) and determine the effect of Bardoxolone methyl in pulmonary hypertension associated with connective tissue disease, interstitial lung disease, and idiopathic etiologies, including subsets of patients with WHO Group III or WHO Group V PH following 16 weeks of study participation.

Change From Baseline Though Week 16 in 6-Minute Walk Distance (6MWD) for Bardoxolone Methyl Compared to Placebo

Baseline through Week 16 · meters

Part 1: Dose-Ranging Bardoxolone Methyl 2.5 mg/Part 2: Open-Label32.5 ± 29.14 meters
Part 1: Dose-Ranging Bardoxolone Methyl 5 mg/Part 2: Open-Label24 ± 30.08 meters
Part 1: Dose-Ranging Bardoxolone Methyl 10 mg/Part 2: Open-Label3.4 ± 31.28 meters
Part 1: Dose-Ranging Bardoxolone Methyl 20 mg/Part 2: Open-Label-3.2 ± 39.53 meters
Part 1: Dose-Ranging Placebo 2.5 mg/Part 2: Bardoxolone Methyl 2.5 mg20.3 ± 13.08 meters
Part 1: Dose-Ranging Placebo 5 mg/Part 2: Bardoxolone Methyl 5 mg24.6 ± 59.4 meters
p-value0.8133
Mean Difference (Net)-1.74 (95% CI -16.22–12.74)

Открыть в BENITIONS Открыть на ClinicalTrials.gov

Все исследования

Страница обобщает открытые данные ClinicalTrials.gov. Это не медицинская и не инвестиционная рекомендация. Обратитесь к врачу.